# GSK (GSK) Q2 2026 earnings

Results filed 2026-07-28 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/gsk/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1131399/000165495426006949/0001654954-26-006949-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

GSK launched an 'Accelerate Growth' programme, lifting planned phase III trial starts in 2026 to 20+ from 10, as it bets on a late-stage pipeline across oncology, respiratory, hepatology and vaccines.

GSK's growth came from Specialty Medicines. Long-acting HIV injectables delivered 80% of HIV growth, and Nucala, Benlysta and Jemperli all grew. Arexvy and meningitis vaccines also rose. The older respiratory portfolio shrank, with Trelegy hit by US Medicare benefit design changes and pricing pressure. GSK stopped camlipixant in refractory chronic cough after phase III results and bought two lung cancer medicines, Jideytro and neladalkib.
Management plans to speed up 7 late-stage assets across 18 indications. It will open a new R&D centre in Cambridge and fund this with a 3-year savings programme, aiming for sales above £40 billion by 2031. The tension is timing: the dolutegravir patent expires in 2028-2030, while the growth assets must prove themselves, and cost cuts must be reinvested without weakening launches.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Turnover | £8.4 billion | +5% AER; +5% CER | GAAP |
| Total operating profit | 481 | (76)% AER; (75)% CER | GAAP |
| Total operating margin | 5.7% | (19.6ppts) AER | GAAP |
| Total EPS | 10.8p | (69)% AER and CER | GAAP |
| Core EPS | 50.5p | 9% AER and CER | non-GAAP |
| Core operating profit | 2,800 | 6% AER; 7% CER | non-GAAP |
| Free cash flow | £2.0 billion |  |  |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Specialty Medicines | £3.8 billion | +14% |
| HIV | £2.1 billion | +10% |
| Respiratory, Immunology & Inflammation | £1.1 billion | +19% |
| Oncology | £0.6 billion | +17% |
| Vaccines | £2.3 billion | +8% |
| Arexvy | £0.2 billion | +>100% |
| General Medicines | £2.3 billion | -9% |
| Trelegy | £0.8 billion | -7% |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Turnover growth | full-year 2026 (at CER) | 3% to 5% |
| Core operating profit growth | full-year 2026 (at CER) | 7% to 9% |
| Core EPS growth | full-year 2026 (at CER) | 7% to 9% |
| Core tax rate | full-year 2026 | 17.5% |
| Royalty income | full-year 2026 | £850-900 million |
| Dividend | full-year 2026 | 70p |
| Accelerate Growth annual savings | fully realised by 2029 | £1.9 billion |

## Key takeaways

1. **Long-acting HIV injectables now drive HIV growth** LAIs delivered 80% of total HIV growth and made up 35% of US HIV turnover, with Cabenuva and Apretude both growing strongly. This shift matters as dolutegravir loses exclusivity in 2028-2030.
2. **GSK is accelerating seven late-stage assets** Acceleration spans 18 indications in Oncology, Respiratory, Hepatology and Vaccines, and planned phase III starts for 2026 rise to 20+ from 10. GSK has 62 assets in clinical development, 19 of them in phase III.
3. **Lung cancer purchases and ADC data widen oncology** GSK acquired Jideytro (FDA approval) and neladalkib (PDUFA H2 2026), and Ris-Rez showed positive phase III overall survival data in China, described as a first for a B7-H3 ADC. Jemperli also has AZUR-1 data supporting rectal cancer reviews.
4. **Camlipixant discontinued after phase III results** GSK decided not to progress camlipixant in refractory chronic cough following the CALM-1/2 phase III results. It took a £1.3 billion impairment, so the chronic cough bet ends and resources shift to other assets.
5. **Established respiratory products face Medicare and pricing pressure** Trelegy fell 7% as US Medicare benefit design changes and channel mix pricing adjustments cut US volumes and price, while Europe and International grew. The General Medicines guidance now points to a mid-single to low-single digit decline.

## Questions

**What is GSK's main strategic move this quarter?** GSK launched an 'Accelerate Growth' programme to speed up 7 late-stage assets across 18 indications and now expects 20+ phase III starts in 2026, up from 10. It is funded by a 3-year programme targeting £1.9 billion of annual savings by 2029.
**How is GSK preparing for dolutegravir losing exclusivity?** It is shifting HIV toward long-acting injectables, which delivered 80% of HIV growth, and building new growth drivers in oncology, respiratory and hepatology. Management expects stable to improving operating margin through 2028-2030 and sales of more than £40 billion by 2031.
**Which products are growing fastest?** Arexvy, Cabenuva, Apretude, Ojjaara/Omjjara, Jemperli, Nucala and meningitis vaccines grew. Blenrep and Exdensur are early in launch, while Zejula and Trelegy declined.
**What happened with camlipixant?** GSK decided not to progress further development of camlipixant in refractory chronic cough after the CALM-1/2 phase III results. It recorded an impairment of £1,334 million.
**How did the US government agreement affect GSK?** GSK and ViiV Healthcare reached a definitive agreement providing Section 232 tariff relief through 20 January 2029, subject to final implementation. They signed Generous Model participation agreements with CMS effective 15 June 2026, and guidance includes the expected impact.

